Tales of How Great Drugs Were Brought Down by a Flawed Rationale-Letter

In a recent article, Komlodi-Pasztor and colleagues argued that cancer researchers used a flawed rationale to develop inhibitors of mitotic enzymes, such as polo-like kinase 1 (PLK1) and aurora kinases ([1][1]). Scientists had been misled by the success of microtubule-targeting agents (MTA) by